{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T10:48:55Z","timestamp":1792838935440,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jhepr.2025.101512","type":"journal-article","created":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T02:56:23Z","timestamp":1751684183000},"page":"101512","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cystic fibrosis liver disease progression in the era of elexacaftor\u2013tezacaftor\u2013ivacaftor"],"prefix":"10.1016","volume":"7","author":[{"given":"Charlotte","family":"Mouliade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1939-5607","authenticated-orcid":false,"given":"Lucia","family":"Parlati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5934-0320","authenticated-orcid":false,"given":"Stylianos","family":"Tzedakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2398-0396","authenticated-orcid":false,"given":"Mathis","family":"Collier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Bouam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anais","family":"Vallet-Pichard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"D\u2019Halluin-Venier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem","family":"Kanaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislas","family":"Pol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Sogni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0903-9828","authenticated-orcid":false,"given":"Pierre-R\u00e9gis","family":"Burgel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2219-9201","authenticated-orcid":false,"given":"Vincent","family":"Mallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2025.101512_bib1","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMra2216474","article-title":"Cystic fibrosis","volume":"389","author":"Grasemann","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101512_bib2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41572-024-00538-6","volume":"10","author":"Mall","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jhepr.2025.101512_bib3","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1002\/hep.1840360613","article-title":"Liver disease in cystic fibrosis: a prospective study on incidence, risk factors, and outcome","volume":"36","author":"Colombo","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101512_bib4","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.jhep.2004.08.006","article-title":"Epidemiology of liver disease in cystic fibrosis: a longitudinal study","volume":"41","author":"Lamireau","year":"2004","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101512_bib5","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1136\/adc.66.6.698","article-title":"Prevalence of liver disease in cystic fibrosis","volume":"66","author":"Scott-Jupp","year":"1991","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jhepr.2025.101512_bib6","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.jhep.2011.03.028","article-title":"Liver disease in adult patients with cystic fibrosis: a frequent and independent prognostic factor associated with death or lung transplantation","volume":"55","author":"Chryssostalis","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101512_bib7","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/MPG.0000000000001728","article-title":"Variceal hemorrhage and adverse liver outcomes in patients with cystic fibrosis cirrhosis","volume":"66","author":"Ye","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhepr.2025.101512_bib8","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S2213-2600(24)00208-X","article-title":"The expanded French compassionate programme for elexacaftor-tezacaftor-ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study","volume":"12","author":"Burgel","year":"2024","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jhepr.2025.101512_bib9","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101512_bib10","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S2213-2600(17)30215-1","article-title":"Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial","volume":"5","author":"Ratjen","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jhepr.2025.101512_bib11","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101512_bib12","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1097\/HEP.0000000000000646","article-title":"Cystic fibrosis screening, evaluation, and management of hepatobiliary disease consensus recommendations","volume":"79","author":"Sellers","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101512_bib13","unstructured":"Agence Technique de l\u2019Information sur l\u2019Hospitalisation. Aide \u00e0 l\u2019utilisation des informations de chainage. www.atih.sante.fr\/aide-lutilisation-des-informations-de-chainage Accessed 10 July 2025."},{"key":"10.1016\/j.jhepr.2025.101512_bib14","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jhep.2017.03.031","article-title":"Contribution of alcohol use disorders on the burden of chronic hepatitis C in France, 2008-2013: a nationwide retrospective cohort study","volume":"67","author":"Schwarzinger","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101512_bib15","unstructured":"Vaincre la Mucoviscidose & Ined. Registre Fran\u00e7ais de la Mucoviscidose \u2013 Bilan des donn\u00e9es 2023. www.vaincrelamuco.org\/face-la-mucoviscidose\/registre-et-muco-en-chiffres\/valorisation-des-donnees Accessed 10 July 2025."},{"key":"10.1016\/j.jhepr.2025.101512_bib16","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jhep.2021.09.030","article-title":"Burden of liver disease progression in hospitalized patients with type 2 diabetes mellitus","volume":"76","author":"Mallet","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101512_bib17","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jhepr.2025.101512_bib18","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2458-9-33","article-title":"Ecological association between a deprivation index and mortality in France over the period 1997 - 2001: variations with spatial scale, degree of urbanicity, age, gender and cause of death","volume":"9","author":"Rey","year":"2009","journal-title":"BMC Public Health"},{"key":"10.1016\/j.jhepr.2025.101512_bib19","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1016\/j.jhep.2023.02.006","article-title":"Effects of CFTR modulator therapies on liver stiffness and bile flow: a single-centre experience","volume":"79","author":"Calvo","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101512_bib20","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jcf.2021.07.018","article-title":"Lumacaftor-ivacaftor effects on cystic fibrosis-related liver involvement in adolescents with homozygous F508 del-CFTR","volume":"21","author":"Drummond","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jhepr.2025.101512_bib21","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jcf.2020.06.015","article-title":"Lumacaftor\/ivacaftor improves liver cholesterol metabolism but does not influence hypocholesterolemia in patients with cystic fibrosis","volume":"20","author":"Gelzo","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jhepr.2025.101512_bib22","doi-asserted-by":"crossref","first-page":"761","DOI":"10.4254\/wjh.v11.i12.761","article-title":"Lumacaftor\/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients","volume":"11","author":"Kutney","year":"2019","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101512_bib23","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000010","article-title":"Effects of CFTR modulators on serum biomarkers of liver fibrosis in children with cystic fibrosis","volume":"7","author":"Levitte","year":"2023","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhepr.2025.101512_bib24","doi-asserted-by":"crossref","first-page":"411","DOI":"10.4254\/wjh.v14.i2.411","article-title":"Cystic fibrosis patients on cystic fibrosis transmembrane conductance regulator modulators have a reduced incidence of cirrhosis","volume":"14","author":"Ramsey","year":"2022","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101512_bib25","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/liv.15544","article-title":"Increase of liver stiffness and altered bile acid metabolism after triple CFTR modulator initiation in children and young adults with cystic fibrosis","volume":"43","author":"Schnell","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2025.101512_bib26","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/LVT.0000000000000529","article-title":"Have CFTR modulators changed the need for liver and lung transplantation among patients with cystic fibrosis? An analysis of the UNOS database","volume":"31","author":"Mendizabal","year":"2025","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhepr.2025.101512_bib27","doi-asserted-by":"crossref","first-page":"100171","DOI":"10.1016\/j.jhlto.2024.100171","article-title":"Impact of elexacaftor-tezacaftor-ivacaftor in lung transplantation for cystic fibrosis in the United States","volume":"7","author":"Pena","year":"2025","journal-title":"JHLT Open"},{"key":"10.1016\/j.jhepr.2025.101512_bib28","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.jcf.2024.03.011","article-title":"Elexacaftor\/tezacaftor\/ivacaftor use in pediatric cystic fibrosis patients with advanced liver disease","volume":"23","author":"Protich","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jhepr.2025.101512_bib29","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jcmgh.2019.04.013","article-title":"Pathophysiology of cystic fibrosis liver disease: a channelopathy leading to alterations in innate immunity and in microbiota","volume":"8","author":"Fiorotto","year":"2019","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101512_bib30","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1136\/gut.2004.062786","article-title":"Patterns of GI disease in adulthood associated with mutations in the CFTR gene","volume":"56","author":"Wilschanski","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2025.101512_bib31","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jcf.2018.09.001","article-title":"IVACAFTOR restores FGF19 regulated bile acid homeostasis in cystic fibrosis patients with an S1251N or a G551D gating mutation","volume":"18","author":"van de Peppel","year":"2019","journal-title":"J Cyst Fibros"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555925001909?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555925001909?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T23:27:55Z","timestamp":1759879675000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555925001909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2589555925001909"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2025.101512","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cystic fibrosis liver disease progression in the era of elexacaftor\u2013tezacaftor\u2013ivacaftor","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2025.101512","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101512"}}